Ning Wu, MD
Urology · Lake Barrington, ILNPI 1831201128
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $5,111 of the $8,434 with a category attached, or 60.6%. 33 manufacturers reported payments, led by Pfizer at 31.9% of the total.
Across 172 payments — averaging $49.04 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Pfizer$3K
- Procept Biorobotics Corporation$859
- Angiodynamics, Inc.$846
- Sumitomo Pharma America, Inc.$541
- Johnson & Johnson$341
- Ferring Pharmaceuticals Inc.$336
- plus $3K from 27 others
Across 178 payments — averaging $4545.85 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AstraZeneca$202K
- Pfizer$195K
- Dendreon Pharmaceuticals LLC$128K
- AbbVie$63K
- Sumitomo Pharma America, Inc.$55K
- Bluewind Medical$48K
- plus $120K from 8 others
What the payments were for
- Speaking & faculty fees$2,71532%
- Travel & lodging$5937%
- Food & beverage$5,11161%
- Education$150%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Pfizer | 5 | $2,692 |
| Procept Biorobotics Corporation | 9 | $859 |
| Angiodynamics, Inc. | 6 | $846 |
| Sumitomo Pharma America, Inc. | 18 | $541 |
| Johnson & Johnson(2 entities) | 9 | $341 |
| Ferring Pharmaceuticals Inc. | 10 | $336 |
| Dendreon Pharmaceuticals LLC | 10 | $297 |
| Myovant Sciences Inc. | 11 | $279 |
| Coloplast | 21 | $265 |
| AbbVie(2 entities) | 10 | $241 |
| Astellas Pharma US Inc | 9 | $218 |
| Boston Scientific | 5 | $211 |
| AstraZeneca | 5 | $190 |
| Urogen Pharma, Inc. | 3 | $176 |
| Olympus America Inc. | 6 | $162 |
| Rochester Medical Corporation | 1 | $111 |
| Bayer | 4 | $105 |
| Merck | 4 | $93 |
| Axonics, Inc. | 4 | $83 |
| Travere Therapeutics, Inc. | 3 | $70 |
| Antares Pharma, Inc. | 3 | $49 |
| Endo Pharmaceuticals Inc. | 2 | $35 |
| Sanofi | 2 | $32 |
| Blue Earth Diagnostics | 2 | $32 |
| Immunitybio, Inc. | 2 | $31 |
| Novartis | 1 | $31 |
| Verity Pharmaceuticals Inc. | 1 | $20 |
| Laborie Medical Technologies Corp. | 1 | $20 |
| Endo USA, Inc. | 1 | $19 |
| Zyla Life Sciences, Inc. | 1 | $14 |
| Hollister Incorporated | 1 | $12 |
| Neotract Inc. | 1 | $12 |
| Myriad Genetic Laboratories, Inc. | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- XTANDI$2,590
- Nanoknife$623
- AquaBeam Robotic System$619
- ORGOVYX$250
- Erleada$233
- ADSTILADRIN$132
- LYNPARZA$125
- GENERAL ERECTILE DYSFUNCTION$111
- JELMYTO$109
- ZUSDURI$109
How this compares
$8,434 in reported general payments places this provider in the 75th percentile of 550 urology providers in Illinois.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XtandiEnzalutamide | 96 | $1,255,588 |
| OrgovyxRelugolix | 211 | $532,496 |
| MyrbetriqMirabegron | 71 | $78,730 |
| GemtesaVibegron | 19 | $21,024 |
| Tamsulosin Hcl | 981 | $18,285 |
| Finasteride | 503 | $7,066 |
| Dutasteride | 119 | $4,439 |
| Tolterodine Tartrate ErTolterodine Tartrate | 32 | $4,309 |
| Silodosin | 33 | $3,632 |
| Oxybutynin Chloride ErOxybutynin Chloride | 113 | $3,034 |
| Testosterone Cypionate | 38 | $2,811 |
| Testosterone | 23 | $2,312 |
| Potassium Citrate ErPotassium Citrate | 15 | $1,723 |
| Trospium Chloride ErTrospium Chloride | 14 | $1,104 |
| Solifenacin Succinate | 27 | $759 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Astellas Pharma US IncXtandi, Myrbetriq | $218 | $1,334,318167 claims |
| Sumitomo Pharma America, Inc.Orgovyx, Gemtesa | $541 | $553,520230 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 550 urology providers in Illinois.
Other urology in Lake Barrington
- Tamra LewisLake Barrington$36K
- Mark BrandtPark Ridge$1.3M
- Aaron BergerChicago Ridge$583K
- Gary SteinbergChicago$529K
- Simone CrivellaroChicago$526K
- Brian HelfandChicago$517K
- Ashley RossChicago$404K
- Kevin McVarySpringfield$372K
- Richard HarrisMelrose Park$363K
- Amy KrambeckChicago$356K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.